AU2010298020B8 - Combination - Google Patents

Combination Download PDF

Info

Publication number
AU2010298020B8
AU2010298020B8 AU2010298020A AU2010298020A AU2010298020B8 AU 2010298020 B8 AU2010298020 B8 AU 2010298020B8 AU 2010298020 A AU2010298020 A AU 2010298020A AU 2010298020 A AU2010298020 A AU 2010298020A AU 2010298020 B8 AU2010298020 B8 AU 2010298020B8
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010298020A
Other languages
English (en)
Other versions
AU2010298020B2 (en
AU2010298020A1 (en
AU2010298020A8 (en
Inventor
Kurt R. Auger
Kurtis Earl Bachman
Tona M. Gilmer
James G. Gregor Jr.
Joel David Greshock
Sylvie Laquerre
Li Liu
Shannon Renae Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2010298020A1 publication Critical patent/AU2010298020A1/en
Publication of AU2010298020B2 publication Critical patent/AU2010298020B2/en
Application granted granted Critical
Publication of AU2010298020B8 publication Critical patent/AU2010298020B8/en
Publication of AU2010298020A8 publication Critical patent/AU2010298020A8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2010298020A 2009-09-28 2010-09-28 Combination Ceased AU2010298020B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24626509P 2009-09-28 2009-09-28
US61/246,265 2009-09-28
US38573810P 2010-09-23 2010-09-23
US61/385,738 2010-09-23
PCT/US2010/050495 WO2011038380A2 (en) 2009-09-28 2010-09-28 Combination

Publications (4)

Publication Number Publication Date
AU2010298020A1 AU2010298020A1 (en) 2012-04-19
AU2010298020B2 AU2010298020B2 (en) 2013-09-12
AU2010298020B8 true AU2010298020B8 (en) 2013-10-10
AU2010298020A8 AU2010298020A8 (en) 2013-10-10

Family

ID=43796526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010298020A Ceased AU2010298020B8 (en) 2009-09-28 2010-09-28 Combination

Country Status (13)

Country Link
US (1) US20120245180A1 (https=)
EP (1) EP2482819A4 (https=)
JP (1) JP2013505962A (https=)
KR (1) KR20120099217A (https=)
CN (1) CN102665719A (https=)
AU (1) AU2010298020B8 (https=)
BR (1) BR112012006968A2 (https=)
CA (1) CA2775874A1 (https=)
EA (1) EA201270475A1 (https=)
IL (1) IL218846A0 (https=)
MX (1) MX2012003779A (https=)
WO (1) WO2011038380A2 (https=)
ZA (1) ZA201202258B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2943199A1 (en) * 2013-01-09 2015-11-18 Glaxosmithkline Intellectual Property (No. 2) Limited Combination
WO2014169843A1 (en) * 2013-04-18 2014-10-23 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
WO2018126192A1 (en) * 2016-12-30 2018-07-05 Children's Medical Center Corporation Map2k1 (mek1) as a therapeutic target for arteriovenous malformations and associated disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
WO2008144463A1 (en) * 2007-05-18 2008-11-27 Smithkline Beecham Corporation Quinoline derivatives as pi3 kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PE20060608A1 (es) * 2004-10-13 2006-08-22 Wyeth Corp Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
TW200815429A (en) 2006-04-11 2008-04-01 Smithkline Beecham Corp Thiazolidinedione derivatives as PI3 kinase inhibitors
CN101528231A (zh) * 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
WO2008144463A1 (en) * 2007-05-18 2008-11-27 Smithkline Beecham Corporation Quinoline derivatives as pi3 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical Cancer Research, 2009, vol. 15, no. 14, pp. 4649-4664 *

Also Published As

Publication number Publication date
EA201270475A1 (ru) 2012-11-30
AU2010298020B2 (en) 2013-09-12
BR112012006968A2 (pt) 2019-09-24
US20120245180A1 (en) 2012-09-27
EP2482819A2 (en) 2012-08-08
MX2012003779A (es) 2012-06-01
WO2011038380A3 (en) 2011-09-15
AU2010298020A1 (en) 2012-04-19
JP2013505962A (ja) 2013-02-21
IL218846A0 (en) 2012-06-28
AU2010298020A8 (en) 2013-10-10
EP2482819A4 (en) 2013-02-20
WO2011038380A2 (en) 2011-03-31
CN102665719A (zh) 2012-09-12
KR20120099217A (ko) 2012-09-07
ZA201202258B (en) 2012-10-31
CA2775874A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
AU2010307043B2 (en) Combination
AU2010298020B8 (en) Combination
US20150094321A1 (en) Combination
US9402846B2 (en) Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer
US20180214451A1 (en) Combination
US20130109705A1 (en) Combination
PT2501379E (pt) Associação
JP2013536192A (ja) 組み合わせ

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 26 , NO 14 , PAGE(S) 1964 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GLAXOSMITHKLINE LLC, APPLICATION NO. 2010298020 UNDER INID (72) CORRECT THE CO-INVENTOR TO GREGER JR., JAMES G.

Free format text: IN VOL 27 , NO 35 , PAGE(S) 5194 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME GLAXOSMITHKLINE LLC, APPLICATION NO. 2010298020 UNDER INID (72) CORRECT THE CO-INVENTOR TO GREGER JR., JAMES G.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired